On July 18, 2019 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, reported its consolidated first-half revenues for the period ending June 30, 2019 (Press release, Theradiag, JUL 18, 2019, View Source;utm_medium=rss&utm_campaign=theradiag-announces-first-half-revenue-up-9 [SID1234537596]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As of 30th June 2019, Theradiag posted first-half revenues of €5.0 million in 2019, up 9% from €4.6 million in H1 2018.
Theranostics posted a 12% growth, primarily driven by LISA TRACKER kits for routine use, for which sales exceeded €2.0 million in the first half of 2019 (vs. €1.8 million in H1 2018).
The partnership entered into with IDS during the first half, covering R&D and the exclusive distribution of TRACKER kits in 33 new countries (including Germany, Latin America and the Middle East) is well underway and is progressing according to plan. The development of the next generation of automated technologies is making progress and will allow to speed up the automation of diagnostics. This solution, providing laboratories with greater flexibility and efficiency, will further enhance Theradiag’s competitive advantage. Regarding the marketing of the innovative TRACKER range, training sessions have begun in certain priority regions, and are being rolled-out as planned.
The Diagnostic In Vitro (IVD) business posted revenue growth of 7%, amounting to €2.9 million in the first half of 2019, including significant non-recurring instrumentation sales.
"The growth recorded in the first half is encouraging, and reflects the efforts made at the start of the year to set up business agreements and continue to develop our unique range of monitoring tests. All of our actions are taken in the aim of constantly innovating and improving our tests, offering patients clinical benefits and bringing medico-economic advancements to the healthcare system. This first half has shown that when the key elements of our business model are firmly in place, we see results. We remain focused on our targets for the year: keep innovation at the heart of our positioning, prioritize growth, particularly abroad – with a focus on operations in the United States. Theradiag has confirmed its goal to continue improving its financial indicators, in order to return to profitability from the end of 2019." commented Bertrand de Castelnau, Theradiag’s Chief Executive Officer.
Pierre Morgon, Chairman of the Theradiag Board of Directors added: "The Theradiag team continues to implement its strategy of setting up partnerships focusing on theranostics. By enhancing the quality and performance of testing solutions in this segment, the company is shifting its focus towards more profitable products."
Next financial press release
Interim 2019 results on Thursday, September 19, 2019, after market close